- Home
- RANI
as 03-28-2025 4:00pm EST
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 55.3M | IPO Year: | 2021 |
| Target Price: | $11.33 | AVG Volume (30 days): | 157.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.24 - $8.75 | Next Earning Date: | 05-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Rani Therapeutics Holdings Inc. News
RANI Breaking Stock News: Dive into RANI Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewswire
4 days ago
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Zacks Small Cap Research
a month ago
RANI: Impressive Bioavailability for RT-116
Simply Wall St.
a month ago
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week
MT Newswires
2 months ago
Rani Therapeutics Discloses Progress in Oral Obesity Treatment; Shares Surge Premarket
GlobeNewswire
2 months ago
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
Zacks Small Cap Research
4 months ago
RANI: Third Quarter Update
GlobeNewswire
4 months ago
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Compare RANI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RANI Rani Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.